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Abstract
The digitization of society and academic research endeavours have led to an explosion of interest in the potential uses of
population data in research. Alongside this, increasing attention is focussing on the conditions necessary for maintaining a
social license for research practices. Previous research has pointed to the importance of demonstrating ‘‘public benefits’’
from research for maintaining public support, yet there has been very little consideration of what the term ‘‘public
benefits’’ means or what public expectations of ‘‘public benefits’’ are. In order to address this pressing issue a series of
deliberative workshops with members of the public were held across Scotland in May and June 2017. The workshops
aimed to engage a cross-section of the Scottish population in in-depth discussions of the ways that the public – or
publics – might benefit from data-intensive health research. The findings reported here discuss workshop participants’
understandings and expectations of health research; who they considered to be ‘‘the public’’ that should benefit from
health research and; in what ways they felt ‘‘the public’’ should benefit. Workshop participants’ preference was clearly for
the widest possible public benefit to be felt by all, but they also acknowledged the value in research aiming to primarily
benefit vulnerable groups within society. A key focus of discussions was the extent to which workshop participants were
confident that potential public benefits would be realised. A crucial consideration then is the extent to which mechan-
isms and political support are in place to realise and maximise the public benefits of data-intensive health research.
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Background
The digitization of society and academic research
endeavours have led to an explosion of interest in the
potential uses of population data in research (McGrail
et al., 2018); this is particularly true in relation to health
research (e.g., Aitken et al., in press; Wellcome Trust,
2015). However, recent years have also brought a
number of public controversies, particularly regarding
proposed uses of health data (e.g., Carter et al., 2015;
Garrety et al., 2014). Two high-profile examples from
the UK are the failed introduction of the care.data
scheme to link hospital and GP records (Ramesh,
2014) and Google Deep Minds’ involvement in process-
ing health data at an NHS Trust in London (Hodson,
2016). In the case of care.data, public opposition to the
programme had significant impacts and resulted in the
programme being put on hold. Such controversies have
drawn attention to the importance of engaging with
members of the public to ensure that data is used in
ways which align with public values and interests to
ensure that public concerns are adequately addressed.
This is essential for developing and maintaining a
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social licence for current and future practices (Carter
et al., 2015).
The growing interest in potential uses of population
data, and the increasing recognition of the importance
of ensuring a social licence for these uses, has resulted
in considerable interest in understanding public atti-
tudes and views on these topics (e.g., Aitken et al.,
2016; Davidson et al., 2013; Wellcome Trust, 2016).
Accordingly there is a fast-growing body of inter-
national literature reporting findings of studies examin-
ing public attitudes towards data and health-related
data science practices (Aitken et al., 2016). A consistent
theme to emerge through this literature is the import-
ance of demonstrating ‘‘public benefits’’ from research
using population data (e.g., Davidson et al., 2013).
Much of the qualitative research undertaken has dis-
cussed perceived ‘‘trade-offs’’ between risks to individ-
uals (e.g., loss of privacy) and broader public benefits of
research. In a systematic review of literature on public
attitudes towards data linkage for health research it was
found that ‘‘assurances that research would bring about
public benefits – or at least that it had the potential to
bring about such benefits – were widely reported to be
fundamental for ensuring public support or accept-
ance’’ (Aitken et al., 2016). While previous research
has revealed different sets of expectations around
‘‘public benefits’’ when research is conducted by
public sector or commercial organisations (Davidson
et al., 2013), on the whole, this literature has not exam-
ined how members of the public conceptualise ‘‘public
benefits’’ or what their expectations are of the ways in
which research might bring ‘‘public benefits’’ (Scott
et al., 2018).
‘‘Public benefits’’ are emphasised in research and
governance processes, providing justification for the
use of health-related and other data generated in a
range of ways and promises of beneficial outputs and
outcomes. Many governance mechanisms which con-
trol access to population health data require demon-
strable public benefit as an element of the approvals
processes before permission is granted for researchers
to use ‘‘Big Data’’ for health and social research. For
example, projects in Scotland that require access to
population health data have to apply to the Public
Benefit and Privacy Panel (PBPP) and are required to
demonstrate that ‘‘any impact on individual privacy is
clearly outweighed by the public benefit resulting from
the processing [of the data]’’ (PBPP, no date: 3). Yet,
despite being of operational significance, the concept of
‘‘public benefit’’ remains under-theorised and little con-
sideration is given to what this means in practice. As
Scott et al. (2018) have observed ‘‘public benefits’’ are
‘‘variously glossed over as impacts that are ‘in the
public interest’, ‘for the greater good’, or ‘leading to
the improvement of health, education or economic
and social well-being’’’ (Scott et al., 2018: 21). Given
the importance of ‘‘public benefits’’ for public accept-
ability of data uses, and its central role in determining
which researchers get access to data for what purposes,
it is essential that a better understanding of what the
term means is generated in a way that is grounded in
public views. This paper aims to provide a first step in
developing such an understanding. It draws on the
results of three deliberative workshops with a broad
range of publics, organised as part of a programme of
public engagement research around data linkage and
sharing for health research. The workshops focussed
on the meanings and expectations publics held and
formed regarding such research use and the paper
maintains that such formulations should inform
research policy and governance in health-related data
science.
Deliberative methods and mini-publics
Deliberative forms of public engagement have been
used to examine and address public interests in a wide
range of policy areas including: health (Mitton et al.,
2009); e-health (King et al., 2010); nanotechnology
(Pidgeon and Rodgers-Hayden, 2007); natural resource
management (Halseth and Booth, 2003); transport
planning (Bickerstaff and Walker, 2001); waste man-
agement (Petts, 2005); and environmental policy
(Owens et al., 2004). These approaches to public
engagement are seen as means of increasing civic
engagement and ensuring that plans or policies are rele-
vant to affected publics/communities (Coleman and
Gotze, 2010).
Deliberative public engagement methods represent
fora for developing public-spirited reasoning to reach
collective agreements (Parkinson, 2004: 379). In the
ideal of public deliberation ‘‘no force except that of
the better argument is exercised’’ (Habermas, 1975:
108). Deliberation should engage with both reasons
and emotions to enable diverse forms of expression
and argumentation and bring about mutual under-
standing (Escobar, 2011; Morrell, 2010). ‘‘For the indi-
viduals involved, this process requires an open mind, a
spirit of reciprocity, and acceptance of the validity of
others’ arguments’’ (Niemeyer, 2011: 105).
A well-established approach to deliberative public
engagement is that of ‘‘mini-publics’’. A mini-public is
a deliberative forum bringing together a group of ran-
domly selected members of the public in order to reflect
the range of demographic and attitudinal characteris-
tics from the broader population – e.g., age, gender,
income, opinion (Roberts and Escobar, 2015). As
such, it is intended that the mini-public represents a
microcosm of ‘‘the public’’ (Roberts and Escobar,
2015). Engagements with a mini-public involve a mix
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of information provision and deliberation (Roberts and
Escobar, 2015). Deliberations typically take place in
small groups and are facilitated by neutral facilitators.
Through this process participants may revise or
strengthen their initial views both in response to infor-
mation and evidence presented as well as from exchan-
ging ideas with other participants. As such it is
important that the mini-public includes a range of per-
spectives and viewpoints.
Through a deliberative process mini-publics often
aim to produce a statement, recommendation or
report to inform policy-making processes regarding
the issue under consideration. Such outputs set out pos-
itions reached through consideration of diverse per-
spectives and as such reflect civic-minded positions
rather than private interests.
Methods
In order to engage mini publics in characterising public
benefit, a series of three deliberative workshops with
members of the public were held across Scotland in
May and June 2017. The workshops engaged a cross-
section of the Scottish population in in-depth discus-
sions of the ways that the public – or publics – might
benefit from data-intensive health research.
Three locations were chosen for these workshops to
reflect different demographic characteristics. The first
workshop was held in Perth, a small city in a largely
rural region of central Scotland. The second workshop
was held in Glasgow, Scotland’s largest city. The third
workshop was held in Aberdeen, a city located in the
North East of Scotland. This geographic spread
enabled the workshops to engage with and reflect the
interests and perspectives of the Scottish public living in
very different contexts and localities.
Following the mini-publics approach, workshop
participants were recruited using quota sampling to
reflect key demographic characteristics of the local
populations in each location. Quotas were set on
gender, age, professional background and level of
trust in institutions (based on an attitudinal question
in the sampling questionnaire). We aimed to have 20–
25 participants in each workshop. In Perth there were
25 participants: 15 women and 10 men; in Glasgow 21
participants: 11 women and 10 men; and in Aberdeen
23 participants: 12 women and 11 men. In all groups
people were aged between their early twenties and late
seventies and included a mix of those unemployed,
employed part time and in full-time employment.
Participants were recruited in person on the street in
each of the three cities. This method was chosen since
it was considered more robust than recruiting from
other pre-existing ‘‘panels’’, because participants are
less self-selecting and so tend to be more representative
of the population and are less likely to be pre-condi-
tioned by having previously taken part in research.
Face-to-face recruitment also promotes participation
compared to written recruitment (Tausch and
Menold, 2016). Recruitment can be undertaken in the
immediate run up to the events, so drop outs are less
likely; and, participants have already met people
involved in the study and participated in an initial on-
street survey, so are more likely to agree to further,
more intensive participation (Sixsmith et al., 2003).
Potential participants were given a letter containing a
brief description of what would be involved in the
event; the date, timing and location; and a map to the
venue and were contacted by phone two days before
the event was due to take place in order to confirm
their participation and to enable any drop outs to be
replaced.
On the day of the event, participants were provided
with further information about the study and the ways
that data would be recorded and used and the potential
outcomes of the research. Participants then completed a
consent form. At the end of the workshop participants
received £80 in cash as a thank you for their participa-
tion. This amount was chosen to reflect current best
practice and a reasonable estimate of the necessary
amount of money to ensure participation in a full day
event taking account of the need to make the event
accessible to everyone including those with childcare
requirements or living outside of the city.
The workshops were day events beginning at 10 am
and ending at 4 pm. The workshops were run in such
a way as to ensure a relaxed and informal atmosphere
to encourage open and fluid conversations. The day
was structured around a mix of facilitated small group
and plenary discussions, brief presentations and videos
to stimulate discussions and deliberation. While infor-
mation provision was important for stimulating
discussions, presentations were kept brief and
throughout the day the emphasis was on deliberation
and active involvement of participants. Topic guides
were developed for each of the group discussions but
these were used flexibly to allow conversations to
follow emerging topics of interest and to enable par-
ticipants to shape the agenda of the workshops.
Discussions were facilitated from a neutral perspective
and participants were encouraged to speak openly and
freely. The presentations were delivered by members
of the research team who also facilitated the discus-
sions. The research team consisted of social scientists
interested in understanding social and ethical dimen-
sions of data-intensive health research, these interests
were explained at the outset of the workshop and it
was made clear that the research team did not intend
to persuade or convince participants of the merits or
otherwise of proposed uses of population data but
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rather were interested in understanding public views
around these.
At the beginning of the workshops participants were
asked to agree a set of ground rules for the day.
Participants suggested potential ground rules which
were then agreed by the whole group. Across each of
the workshops the ground rules created consistently
emphasised the importance of allowing everyone a
chance to speak and respecting differences of opinion.
It was stressed that we were not necessarily aiming to
reach a consensus about the topics that would be dis-
cussed but rather we were interested in hearing the
range of views people might hold about these.
Following this the day began with small group dis-
cussions on the topic of health research very broadly, in
which participants discussed their understandings and
expectations of health research. This was followed by a
presentation introducing the topic of data-intensive
health research and giving an overview of the ways
that data is currently used in health research and the
governance systems in place. Small group discussions
then focussed on data-intensive health research. A
second presentation set out the importance of ‘‘public
benefits’’ as a driver for data-intensive health research.
This was a brief presentation which described the
importance given to ‘‘public benefits’’ for determining
applications for data access and also previous research
identifying ‘‘public benefits’’ as crucial for public
acceptability of data use. The presentation noted the
difficulty in clearly defining the concept of ‘‘public
benefits’’ and led into facilitated small group discus-
sions around what this term means and what people’s
expectations of public benefits would be.
A series of videos were then shown of data scientists
discussing research projects which they had either
recently completed or were planning to undertake.
Videos were used instead of face-to-face presentations
in part as a result of practical challenges associated with
securing participation of data scientists at each of the
three workshops and also because this virtual presence
encouraged participants to be frank and honest in their
responses. The three data scientists gave an overview of
their research, why they considered it important and
what the anticipated public benefits of the research
would be. Following the videos, workshop participants
discussed the extent to which they considered each to
have public benefits.
In the final session of the workshops participants
were asked to come up with statements to answer two
key questions: (1) Who is the public that should benefit
from data-intensive health research and; (2) In what
way should they benefit? Participants were given no
further direction on how they should answer these
questions and were not provided with examples or
options to choose from, but rather were encouraged
to reflect on the discussions over the course of the
day. It was reiterated that we were not aiming to
reach a consensus around these issues but rather
wanted to capture and reflect everyone’s views.
During the workshops all small group discussions
were recorded and detailed notes were taken of the plen-
ary discussions. Following the workshops the record-
ings of the discussions were typed up by the research
team. A narrative account of each of the workshop
sessions was developed through assimilating each of
the researchers’ notes from the events along with the
transcripts from the recordings. Notes from each ses-
sion were collated and key themes and topics were iden-
tified, as well as the identification of nuanced or
divergent perspectives. In reporting the workshop dis-
cussions in the following sections of this paper, we draw
on transcripts of the small group discussions (which
allow verbatim quotes) and detailed notes of the plen-
ary discussions (which do not allow verbatim quotes).
The following sections of this paper will set out the
findings from the workshop discussions and key con-
siderations which emerged as central for meeting public
expectations concerning public benefits from data-
intensive health research.
Findings
Expectations of health research
In the first small group discussion of the day, workshop
participants were asked to describe their expectations of
health research and what they understood the term
‘‘health research’’ to mean. Participants typically
responded by describing health research as being
aimed at improving health or health services, and/or
leading to new treatments. Across each of the work-
shops it was evident that health research was expected
to be aimed at a clear purpose of improving health
outcomes or health services.
Workshop participants described a variety of types
of health research, demonstrating awareness of diverse
forms that such research can take. The examples given
were offered spontaneously by workshop participants.
While some participants described only research under-
taken in clinical settings others gave varied examples
including: surveys; research around lifestyles; research
in laboratories; and audit of health services. These par-
ticipants noted that health research can use a variety of
sources of information including donated organs or
tissue samples, genetic or clinical information as well
as information from medical records or surveys. While
some participants did not initially think of this diversity
of health research, once mentioned by others these
broad approaches and methods were acknowledged as
comprising health research.
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When asked who they would expect to be conduct-
ing health research, in many groups workshop partici-
pants initially discussed health research conducted by
charities and it was clear that this was often the first
type of research that came to mind. Participants often
stated that this was due to having an awareness of this
research as a result of fundraising campaigns, TV
adverts or leaflets (for example from Cancer Research
UK). However, a broader range of research organisa-
tions were also discussed and workshop participants
listed many potential researchers including those
within the NHS, universities, charities or private com-
panies. In most groups the involvement of private com-
panies in health research was a contentious subject.
Private companies were described as having a different
set of objectives from academic or public sector organ-
isations, and in some discussions commercial interests
were conceptualised as being in opposition to public
benefits. However, participants also noted the blurri-
ness of lines between sectors and acknowledged that
university research can also lead to commercial out-
puts. For example, the following discussion reflected
one group’s shifting position as they considered the
potential involvement of private companies in health
research:
F2: the right people would be people in the NHS, in the
medical profession, because they’re not in it for the
money. In my point of view, I don’t want people to
profit from it, from the data
M1: no
M3: but if they could cure someone
F2: but if they could cure someone and then charge
them massively
M1: no financial gain
F2: I don’t want financial gain, yeah
MA: what if a university research group collaborated
with a pharmaceutical company?
F2: Sometimes I would imagine that has to happen
M3: for new drugs
MA: in that situation there may be some profit that
goes with it
F1: yeah, there has to be some profit
M3: without profit there won’t be any progress
F1: you need the companies involved – it’s a necessary
evil
F2: so long as there is good with it
F1: more good than bad
F2: it’s about the balance
M3: It’s never going to be 100 per cent
F2: some people are only going to be in it for the money
M1: that’s just the way it is. (Perth, Group 1)
Similarly when asked about their expectations of uni-
versity researchers, participants typically acknowledged
that academic research is not necessarily independent of
any financial interests:
M2: It would depend where the university was getting
the funding from. There’s a chance the university could
be getting their funding from a pharmaceutical
company.
F2: Again, that’s trust, isn’t it? You’re trusting those
researchers to be ethical with their findings, because
you do get the picture that the money issue is always
breathing down their neck
M3: I would think, or I would hope, that universities
and that were more neutral, that they don’t have any-
thing to win or lose out of it. They’re looking at the
bigger picture. (Glasgow, Group 3)
In discussing the different types of researchers who may
be involved in health research participants acknowl-
edged that there can be a role for commercial organisa-
tions but concerns were raised about funding and the
interests that go along with that. Funding of research
was an area of interest in discussions across the work-
shops. It was acknowledged that research could be sup-
ported by either public or private funding. Some
participants expressed mistrust of private research fun-
ders, for example a large number of participants con-
tended that private companies would suppress research
results if it enabled them to increase their profits. In
particular, a number of participants stated that they
believed that a ‘‘cure for cancer’’ may have already
been found but that pharmaceutical companies are
holding on to it to make the most money:
F1: People always say there’s no cure for the common
cold – so what chance do we have of finding cures for
cancer if there’s no research into it
M1: some people say they have got a cure for cancer
but they’re holding it back to sell to the highest bidder
F1: Conspiracy theories
M1: There’s truth in it
F2: Everybody thinks that, the higher authorities are all
in it for what they can make out of it
M2: are they withholding a cure?
F2: unfortunately not everyone has a heart, they don’t
care enough. (Perth, Group 1)
M2: I believe that there is research that has been done
that has proven to actually help benefit certain illness
and whatnot but nothing will be done about it because
the pharmaceutical companies are making far too much
money from selling other products to help combat these
things.
M4: I think also the problem is that you have huge com-
panies that aremaking billions andbillions of pounds and
that obviously promotes distrust because they’re making
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so muchmoney. But at the same time, you need that level
of funding to be able to produce the advances. An exam-
ple would be the Ebola crisis last year, they did ten years’
worth of research in nine months because the WHO just
piled billions into it, and they need that funding level, and
they got a cure out of it. But then at the same time,
because they’re so profitable, it’s not necessarily ethical.
(Glasgow, Group 3)
There was concern that research conducted or funded
by private companies would be directed at maximising
profits rather than maximising public benefits. For
example, one participant in Aberdeen stated:
The money in research is directed at money-making
things. Like, weight loss gets a lot of money put into
it, more than malaria, which affects people a lot more
than being overweight, which is generally, or can be, a
cosmetic thing. It’s not down to illness. Not always –
sometimes it is – but, malaria, if they found a cure for
that, billions of people, that would be their life
improved. So . . .where the money is they’ll research.
(F1, Aberdeen, Group 3)
Furthermore, there was also discussion of the potential
for governments to be involved in suppressing discov-
eries of new cures if they are too expensive or not
aligned with government priorities:
M4: I often wonder if they want to find a cure for it. All
the pharmaceutical companies they’re making millions
out of it. If they find a cure for it, what are they going
to do now?
M1: You could say the same about the government –
does the government really want to find cures? Because,
at the end of the day, the longer people live, the more it
costs to give them everything: pensions, health service,
and what have you. So, do they want us to be living to
100 years old? Probably not.
F2: You lot are a load of doom and gloom!
F3: Five minutes in and we’re into the conspiracy the-
ories! [laughter]
M4: They’ve been researching for maybe twenty years,
you’d think somebody would’ve found a breakthrough
M2: With all the money that’s been ploughed into it.
M4: Do they really want to find a cure for it?
F3: Why would they waste money investing in trying to
find it in the first place?
M1: Cos they’ve got to look like they’re trying to find it
F3: No, they are trying to . . . I’ve never even thought
that they weren’t trying to. They’re doing all the
research and everything, they’re trying to find cures
[. . .]
M2: They make money by giving drugs. The pharma-
cies make money by getting the prescriptions from the
NHS and everything. Everybody makes money from it
so, why would they? They don’t care about the little
person. (Aberdeen, Group 3)
This related to wider discussions around the ways in
which benefits of health research are realised and a
widely held perception that currently the benefits are
not realised equitably across society and that different
groups or people in different locations across the UK
experience health services differently as well as experi-
encing different health outcomes.
Throughout these discussions a recurring theme was
that the potential benefits of health research were not
always or consistently realised. A range of factors were
noted as limiting the realisation of public benefits from
health research, these included commercial interests,
political priorities and limited public funding.
Who is the public that should benefit from
data-intensive health research?
When posed the question ‘‘who is the public?’’, work-
shop participants typically treated this as a straightfor-
ward and obvious question. Across all of the
workshops participants almost always initially
responded by stating that: ‘‘the public is everyone’’.
However, these responses quickly became more
nuanced and complex when discussions moved to
think about what this meant in practice and, in particu-
lar about the ways in which ‘‘the public’’ could benefit
from data-intensive health research. Two key consider-
ations emerged as important in conceptualising ‘‘the
public’’. These were scale and need.
Firstly, there were discussions around scale with
workshop participants expressing a range of views on
whether the public should be conceptualised as every-
one globally, nationally or locally.
M3: It’s us – all of us. Everyone in the world.
F4: It’s society. As in, what stands below the govern-
ment. The individual who goes to work every day,
doesn’t put a suit on, doesn’t sit and make a decision
on what our lives are going to be doing. (Perth,
Group 3)
F2: Presumably that’s just us, Joe Bloggs.
F3: Everyone
F2: We’re the public, are we not?
EC: Are we? [...] When you think about ‘‘the public’’,
who’s in your mind?
F2: Myself
M1: Working class people.
F5: The people that the research affects.
M2: Or benefits.
F3: I just think everyone.
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EC: In Scotland?
F3: Just everyone.
EC: In the world?
F1: In the whole wide world.
F2: It depends what the research is about. If it’s merely
based on Scotland, it would be the people of Scotland, I
would think. People of voting age. (Perth, Group 2)
There was generally a preference that ‘‘the public’’
should be considered as inclusively as possible, meaning
that there was a preference for research to benefit the
widest possible public (i.e., benefit the maximum
number of people). One workshop participant even
stated that we should think of the public as ‘‘everyone
in the universe’’ – this was stated only partially as a joke
and demonstrated a strong preference to be as inclusive
as possible when thinking about ‘‘the public’’.
However, the second key consideration – need – led
to different sets of preferences. Workshop participants
acknowledged that the findings and outcomes of
research can have greater or lesser potential impact
for different groups within the public. For example, it
was acknowledged that health research could – and in
many instances should – have the greatest benefits for
people with major health issues or groups affected by
particular conditions related to the subject of the
research. This led to recognition of the value of
health research being targeted at vulnerable groups
who would potentially benefit the most. In this sense
public benefits were conceptualised as being benefits to
particular smaller groups within the public rather than
benefits to the wider public as a whole. However, it was
also noted that while the immediate benefits of research
might be targeted at those considered to be in greatest
need, in the long-term this would be of benefit to every-
one in society, suggesting that the two positions were
far from incompatible.
M1: I think it’s everybody because even if you’re not
aware of it or affected by it, that doesn’t mean it’s not
of relevance to you.
F3: Just because you’re not associated with it at the
time it doesn’t mean it won’t impact you later on in
your life. (Perth, Group 3)
In what ways should members of the public
benefit?
When asked in what ways the public should benefit
from data-intensive health research, a very broad set
of responses was given, demonstrating wide-ranging
conceptualisations of ‘‘public benefits’’. Responses indi-
cated that workshop participants considered that
public benefits should be as broad as possible. One
participant stated that the public should benefit ‘‘in
every way they are entitled to’’ and another stated
that the public should benefit in ‘‘the most beneficial
way possible’’. These responses highlight workshop
participants’ recognition of the wide range of public
benefits that could be possible. Many participants
were clearly avoiding giving answers which might
limit the ways that benefits were pursued and demon-
strated a clear preference that benefits should be max-
imised across society in whatever form they take.
Given that workshop participants had previously
described the purpose of health research as being pri-
marily about leading to improvements in health and/or
health services, it is unsurprising that many responses
related to this theme. Many participants suggested that
finding cures for diseases and making new drugs avail-
able was a clear way in which members of the public
should benefit. In particular, cancer, dementia and
mental health were often flagged as pressing conditions
about which more research was needed. More broadly
than just cures and increased medicalization, consider-
able time in the discussions focused upon improving
lives; with a focus on health improvement, better qual-
ity of life and enhanced lifestyle, with people living
longer and healthier lives and lives that are less stress-
ful. Linked to better quality of life and outcomes, par-
ticipants suggested that future generations should be
thought about so they do not face similar health and
lifestyle burdens, with better understanding and imple-
mentation of preventative measures. Participants also
stated that benefits of research should be measurable,
through better quality care and services. Improved allo-
cation of resources was also a way in which participants
thought the public could benefit.
Public benefits were also conceptualised in less direct
ways. For example, participants considered that there
can be ‘‘knock-on effects’’ of small numbers of people
benefiting from health research. Improving health and/
or quality of life of vulnerable groups was expected to
lead to wider benefits for society. Therefore, participants
thought that there should be proactiveness to address
particular needs of vulnerable communities to ensure
that communities, and society as a whole, can lead
better quality lives. This was also described as requiring
empowerment of individuals and communities.
The public were also described as benefitting from
research through the creation and dissemination of new
knowledge. Workshop participants suggested that
increasing scientific knowledge is in and of itself a bene-
fit and that members of the public could benefit from
greater engagement with the scientific community. This
led to discussions of the need for science to do more to
publicise research results, and, in particular, to engage
with the public. However, it was frequently stressed
that it is not sufficient for research to create new
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knowledge or understanding, rather it is considered
essential that policy makers, governments and/or the
health service act on research findings in order to realise
the potential public benefits.
M5: The point is, it’s about what the outcome of the
research is, because if it says people coming from
poorer backgrounds or deprived areas [are more at
risk of health conditions] . . . is anyone actually going
to spend any money to change it? Or is just a case of–
F2: ‘‘This is the research, we’ve done it, that’s it’’.
M4: The findings can be there but nothing’s actually
done. (Aberdeen, Group 3)
These discussions around the ways in which the
public might benefit from data-intensive health
research revealed openness to the possible forms
public benefits could take and an unwillingness to
set limits or constraints on what public benefits
might be. However, there was considerably more
interest in the likelihood of the benefits being realised.
Reflecting earlier discussions around perceived bar-
riers to realising benefits of health research, partici-
pants across all workshops were less concerned with
what the benefits would be compared with assurances
that any benefits would be realised. While noting that
knowledge itself brought benefits, the participants
wanted reassurance that further public benefits
could ensue through applying knowledge to improve
lives.
Responses to three research projects
The preceding sections have focussed on workshop
participants’ discussions of public benefits from data-
intensive health research at a general level. The work-
shops moved on to encourage participants to consider
the ways in which particular research projects might
lead to public benefits.
Workshop participants were shown videos of three
data scientists who presented their research and the
ways in which they considered it would lead to public
benefits. The three research projects presented were
chosen to reflect very different subject matter. Project
A related to admissions to care homes; Project B
related to impacts of air pollution on babies; and
Project C related to evaluating impacts of one particu-
lar illegal drug interception policy.
As a catalyst for discussions, after viewing the
videos workshop participants were asked to vote on
which project they considered to have the greatest
potential public benefits. There was widespread agree-
ment that each of the three research projects had – at
least potential – public benefits. This reflects the find-
ing discussed above that participants recognised the
diverse and varied forms that public benefits might
take, as well as the diverse forms that research itself
might take. However, there were some clear patterns
regarding which projects were regarded most favour-
ably. Voting preferences generally reflected the close-
ness or relevance of research subject matter to
individuals’ lives. For example, older participants
tended to vote for Project A which related to admis-
sion to care homes. At all three of the workshops
Project C (which related to interception of illegal
drugs) consistently received the fewest votes yet was
also always the project which generated the greatest
discussion. The key discussion points which emerged
unprompted in group deliberations related to: who
would benefit from the project; which project would
have the greatest impact; and to what extent work-
shop participants expected that the potential benefits
would be realised.
In discussing their reasons for voting for particular
projects, participants considered which project would
be likely to have the greatest impact. This was discussed
both in terms of which projects would benefit the most
people and which would have the biggest benefit for
those in greatest need – the two key ways in which
these ‘‘mini publics’’ characterised public benefit.
Project A focussing on care homes was seen to be
very relevant in the context of an aging population
with care homes expected to be of increasing relevance
in years to come. Additionally this project was con-
sidered important since it related to benefitting vulner-
able people.
M2: [Care] is putting a huge drain on resources at the
moment. We’re living in an older society.
F3: People are living a lot longer. These are people who
have paid into the pot for so many years and then
they’re just getting left... need to put more resources
into it. (Perth, Group 3)
Similarly, Project B which focussed on air pollution was
considered to potentially benefit the whole of society as
well as the environment and non-human life. Since this
project was focussing on impacts on babies, many
workshop participants regarded it as potentially
having the biggest public benefits as it was starting
‘‘right at the beginning of life’’. This was a point that
was made in all workshops.
F3: For me, if [Project B] was just air pollution, without
the pregnancy component, I probably would have gone
for care homes [Project A]. But because his research is
mixed with the pregnancy, as a mum, I want to give my
children the best start in life.
F2: Anything to do with pregnancy is important – it’s
the start in life. (Aberdeen, Group 3)
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Participants noted that having a poor start in life can
affect the whole of the rest of life.
F3: I voted [for Project B], we all know the risks about
smoking in pregnancy and now its became unacceptable
that women should be smoking because the harm it does
to the baby and now we know that pollution is likely to
be just as bad, no one seems to be bothered about it and
we know the effects it can have on babies, more pollution
smaller babies then it would force them to do something
about it. That would prevent poorer health in childhood
and all the things that go along with being premature
and all the things that go along with it.
F4: I voted for [Project B] too and I did that because it
is the start of life, a baby being born, because it affects
your whole life. I actually liked all of them. I worked in
a dementia unit and I know how it affects everyone, the
whole family, but the baby one was trying to do some-
thing at the start of life. (Perth, Group 3)
Conversely, workshop participants were more sceptical
of the extent to which Project C (focussing on drugs
enforcement) would have a big impact. Some partici-
pants described this as ‘‘fighting a losing battle’’ and
said that ‘‘drugs are going to be used no matter what’’.
Across the workshops drug use was recognised to be an
area of major, but intractable, concern with significant
implications for society. Drugs were described as a big
problem to be tackled, but also a complex social issue.
Much of the discussion about Project C related to the
extent to which this research would actually have an
impact in addressing problems of drug use: it was
described as reaching ‘‘just the tip of the iceberg’’.
This meant that people were less inclined to vote for
this project in comparison to the others, although as the
dialogue below illustrates, people had different kinds of
reservations.
M1: I didn’t vote for it, not because I didn’t think there
would be any benefit but we have been talking about
health data and I just found it much harder to directly
correlate, obviously we are talking about drugs and not
necessarily everyone taking these drugs will be taking
them to a degree which significantly affect their health,
you might get the people who take them now and
again. I just thought it would be very difficult to state
a clear public benefit . . .
F1: with that one it’s hard to see how you could do
something directly with the findings, I mean maybe fur-
ther down the line, but straight away, it would be dif-
ficult to get a clear public benefit from.
M5: I can see the clear public benefit from that but it
looks like a hard fight, it’s just gonna take a long time, I
just felt the other one, for me, was more beneficial.
(Perth, Group 3)
While the subject matter and aims of the project were
widely considered to be of high importance, workshop
participants were not confident that this project would
be able to make a significant difference. This highlights
the importance of demonstrating mechanisms being in
place to enable impact.
Drug use is a more controversial subject compared
with care homes or air pollution so it is not
surprising that Project C generated the most discussion.
Given that workshop participants typically acknowl-
edged that their preferences for particular projects
were influenced by the extent to which they were per-
ceived as having relevance to their own lives, as well as
society more generally, the potential stigma of drug use
and what they saw as its social complexity, might have
had some influence in shaping responses. It is note-
worthy that one workshop participant who spoke
about the ways in which his own life and that of his
friends and family had been affected by drug addiction
made an emotional and passionate plea to fellow par-
ticipants to give Project C greater consideration.
The deliberations regarding the three projects illus-
trate the findings reported in preceding sections of this
paper. The voting exercise was intended as catalyst for
discussions rather than a priority setting exercise and
workshop participants typically stressed that they
appreciated the potential benefits of all three projects.
Not voting for a project did not mean that a participant
did not believe it could bring public benefits. As such
participants recognised and acknowledged the very dif-
ferent types of public benefits which could come from
the three projects. However, the discussions consist-
ently focussed on key considerations (which were not
prompted by the facilitators): which project would be
likely to have the biggest impact, and whether partici-
pants had confidence that potential public benefits
would be realised. These emerged as key themes
throughout discussions at all three of the workshops.
Discussion
Each of the three workshops resulted in open and wide-
ranging discussions leading to nuanced and complex
positions regarding the ways that data-intensive
health research might bring public benefits. The work-
shop discussions demonstrated that ‘‘public benefits’’
were conceptualised in a number of different ways
and participants had varied expectations of what this
implied for actual research practice. Nonetheless, there
was a clear consensus that public benefits should be to
individuals, specific groups and to society more widely.
It is interesting to note that no one spoke of societal
benefits in terms of economic benefit, although this is
often portrayed as a form of public or societal benefit
by governments and funding agencies. For example,
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The European Commission Strategy Centre recently
called data ‘‘the lifeblood of the global economy’’
(European Commission, 2017), whereas benefits to the
economy through new data-driven industries were
never mentioned by workshop participants. Where eco-
nomic dimensions were raised, these related to potential
impacts on individuals or groups within society. For
example, when discussing care homes and the pressures
of an aging population, workshop participants were
typically concerned with the economic impact on indi-
viduals through a pressured care system and how that
affected health and wellbeing. In considering how best
to generate and sustain a social license for health-
related data science, funders and researchers may
need to more clearly articulate how economic benefits
would result in wider social impact.
Workshop participants had a broad and inclusive
approach to conceptualising both the public and
public benefit. They did not perceive a conflict between
desiring wide benefit for society as a whole and promot-
ing the needs of particular groups. Indeed, they recog-
nised the role of indirect public benefits – those
accruing to society when the pressing needs of some
are met. It was generally acknowledged that targeting
benefits for those in need was appropriate and neces-
sary. This resonates with a recent study which exam-
ined public sector professionals’ expectations of public
benefits and found that when evaluating the relative
value of different public benefits some focussed on the
number of people benefitting, others focussed on the
level of need of those benefitting and, for others it
was the potential for long-term impacts (Scott et al.,
2018).
Workshop participants were unwilling to narrowly
define or constrain public benefits and preferred to keep
this definition open recognising the very many forms
public benefits could take. They were more concerned
with the likelihood that benefits would be realised –
that research would make a difference – a theme con-
sistent across all workshops. The discussions high-
lighted the need for action in response to research
findings, suggesting that ensuring impact itself was an
important component of achieving public benefit. They
recognised the wider processes involved in this, beyond
the research community itself to include policy makers
and practice communities. Across all the workshops
there was widespread agreement that, currently, the
benefits of health research are impeded by commercial
or political interests. There was considerable scepticism
of the extent to which necessary mechanisms and pol-
itical support are in place to enable research to lead to
public benefits. This indicates that workshop partici-
pants recognised that the pathways between research
and impact are not straightforward or inevitable and
reflects widespread awareness of the importance of
maintaining relationships between research and
policy – and more broadly science and society. There
was consensus that there needs to be commitment and
willingness by all stakeholders involved in the research
process to implement findings and maximise public
benefits. Workshop participants were much less con-
cerned with what form public benefits would take, com-
pared with seeking assurances that potential benefits
would be realised. Addressing this area of concern
may be vital for securing public support and establish-
ing a social license for future health-related data science
and demands transparency regarding how impact can
be achieved.
Study limitations
The research was undertaken following a ‘‘mini-
publics’’ approach which aimed to engage with a
cross-section of the Scottish population. Participants
were sampled to represent demographic characteristics
broadly representative of local populations in each of
the locations. Nevertheless, the total number of partici-
pants in the study was 69 and as such is not sufficient to
claim that the sample is representative of the wider
Scottish population. Deliberative public engagement
methods are effective for enabling in-depth examination
of participants’ viewpoints and rationales but are time
and resource-intensive which constrained the scope of
this study. The aim of this qualitative, deliberative
research was not to produce a set of findings which
could be generalised or be considered representative.
Rather it intended to explore the ways in which mem-
bers of the public would engage with this important
subject and examine the range of views that would be
expressed. In that context, it is noteworthy that the
findings produced were broadly consistent both within
and between each of the workshops.
The responses reported throughout this paper were
generated through discussion, with few prompts from
the facilitators. The research team did not set out to
examine public views on any particular potential types
of benefits but rather to explore how members of the
public would conceptualise public benefits and what
their expectations are. Future research might usefully
engage the public in discussions of particular potential
outcomes and research aims.
Conclusions
This research has demonstrated the value of engaging
with members of the public to address conceptually,
socially and ethically challenging issues related to cur-
rent and future health-related data science practices.
The social licence for the research use of health and
other ‘‘Big Data’’ needs to be continuously negotiated
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as public expectations, preferences and views shift in
response to changing contexts and experiences. The
boundaries of acceptability will need to be renegotiated
on an ongoing basis to ensure that actual practices align
with public values and concerns. This may be of par-
ticular importance when considering economic benefits,
particularly but not only with respect to commercial
involvement in research (Davidson et al., 2013;
Wellcome Trust, 2016).
The nuanced discussions at each of these workshops
have demonstrated the value of bringing together
diverse groups to discuss conceptually challenging
topics enabling considered and informed opinions to
be developed. As noted by Scott et al. (2018: 32)
‘‘there is a need for further direct engagement with
the public to better understand where their boundaries
of acceptability lie within the context of data sharing’’.
This study reaffirms much of the literature concerning
deliberative public engagement methods, in demon-
strating the value of these methods for informing and
examining public attitudes around complex subject
matter.
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